Alzheimer's Disease and Related Disorders - Full Text View

Purpose

The purpose of this study is to compare characteristics of gait and balance measured among patients with Alzheimer's disease or related disorders separated into 3 groups according to the stage of disease (i.e., pre-dementia, mild and moderate dementia stages); to determine the effects of anti-dementia drugs and vitamin D on cognitive motor abnormalities; and to establish a database at Angers University Memory Centre.

Condition	Intervention
Alzheimer's Disease Gait Apraxia Impaired Cognition	Drug: Drug intervention


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Cross-Sectional
Official Title:	Maladie d'Alzheimer et Maladies apparentées : Caractérisation Des Anomalies Cognitivo-motrices, et Des Effets Des médicaments Anti-démence et de la Vitamine D à Partir de la Mise en Place d'Une Base de données au CMRR du CHU d'Angers

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease Dementia Vitamin D

Drug Information available for: Vitamin D

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease Apraxia

U.S. FDA Resources

Further study details as provided by University Hospital, Angers:

Primary Outcome Measures:

Spatiotemporal gait parameters [ Time Frame: baseline ]


Estimated Enrollment:	700
Study Start Date:	November 2009
Estimated Study Completion Date:	November 2017
Estimated Primary Completion Date:	November 2017 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Group 1 Patients with Mild Cognitive Impairment	Drug: Drug intervention before-after interventional (anti-dementia drugs and/or vitamin D) study Other Name: Anti-dementia drugs and/or vitamin D
Group 2 Patients with Mild Alzheimer's disease or related disorders	Drug: Drug intervention before-after interventional (anti-dementia drugs and/or vitamin D) study Other Name: Anti-dementia drugs and/or vitamin D
Group 3 Patients with Moderate Alzheimer's disease or related disorders	Drug: Drug intervention before-after interventional (anti-dementia drugs and/or vitamin D) study Other Name: Anti-dementia drugs and/or vitamin D

Detailed Description:

Although gait disorders are frequently associated with Alzheimer's disease and related disorders (ADRD), few studies have focused on cognitive motor effects of anti-dementia drugs and vitamin D.

The objectives of this study are to

Compare characteristics of gait and balance measured among patients with ADRD separated into 3 groups according to stages of disease (i.e., pre-dementia, mild and moderate dementia stages)
To determine the effects of anti-dementia drugs and vitamin D on cognitive motor abnormalities
To determine whether motor abnormalities could be associated with cognitive impairments, specifically executive dysfunctions
To establish a database at Angers University Memory Center.

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

All patients of the University Memory Center of Angers University Hospital with respect to the eligibility criteria

Criteria

Inclusion Criteria:

All elderly patients from the University Memory Center of Angers University Hospital.
Able to walk without any walking aid on 15 meters
Mini-Mental Status Examination score > 10
Being affiliated to a social security regime

Exclusion Criteria:

Mini-Mental Status Examination score ≤ 10
Subject suffering from pre-existing impellent disturbances
History of cerebrovascular accident or other cerebro-spinal pathology
Poor workmanship of the written or oral French language
Use of walking aid such as walking frame with wheels or tricycle.
Acute medical or surgical disease in the past 3 months
Refusal to participate (or trustworthy person)
Near visual acuity < 2/10

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01315704

Contacts


Contact: Cedric ANNWEILER, DM	(+33) 241354725	ceannweiler@chu-angers.fr

Locations


France
Cédric ANNWEILER , MD	Recruiting
Angers, France, 49933
Contact: Cedric ANNWEILER, MD (+33)241354725 ceannweiler@chu-angers.fr

Sponsors and Collaborators

University Hospital, Angers

Investigators


Principal Investigator:	Cedric ANNWEILER, MD	Memory Centre of Angers University Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Beauchet O, Barden J, Liu-Ambrose T, Chester VL, Annweiler C, Szturm T, Grenier S, Léonard G, Bherer L, Allali G; Canadian Gait Consortium. Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial. Drugs Aging. 2016 Sep;33(9):665-73. doi: 10.1007/s40266-016-0391-0.

Beauchet O, Launay CP, Allali G, Watfa G, Gallouj K, Herrmann FR, Annweiler C. Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study. BMC Neurol. 2013 Nov 21;13:184. doi: 10.1186/1471-2377-13-184.


Responsible Party:	Cédric ANNWEILER ; MD, Memory Centre of Angers University Hospital
ClinicalTrials.gov Identifier:	NCT01315704 History of Changes
Other Study ID Numbers:	2009-15
Study First Received:	March 11, 2011
Last Updated:	March 14, 2011

Additional relevant MeSH terms:


Apraxias Gait Apraxia Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Psychomotor Disorders	Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms Gait Disorders, Neurologic Vitamins Vitamin D Ergocalciferols Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents

ClinicalTrials.gov processed this record on September 20, 2017

Alzheimer's Disease and Related Disorders (MERE)